{"id":"W2139430929","doi":"10.1016/s0140-6736(12)61853-4","title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","year":2013,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":546,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada); Sunnybrook Health Science Centre; Health Sciences Centre","funders":"ViiV Healthcare","keywords":"Dolutegravir; Raltegravir; Medicine; Emtricitabine; Integrase inhibitor; Abacavir; Lamivudine; Adverse effect; Clinical endpoint; Virology; Internal medicine; Efavirenz; Clinical trial; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006588555,0.0003987231,0.0008577756,0.00008972549,0.0002553745,0.0001265033,0.0003511779,0.00009902829,0.00009376642],"category_scores_gemma":[0.00008978076,0.0001923611,0.0001164114,0.0005211277,0.0001605442,0.0002061225,0.0001089301,0.0006368615,0.0008263007],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00019179,"about_ca_system_score_gemma":0.0001733351,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01303532,"about_ca_topic_score_gemma":0.004393389,"domain_scores_codex":[0.997694,0.0002082345,0.0005215004,0.0005327255,0.0005136925,0.0005298894],"domain_scores_gemma":[0.998049,0.0004014799,0.0002158369,0.001080062,0.0001279798,0.0001256613],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3139771,0.0008699053,0.6629937,0.00002059087,0.0004876085,0.0001155142,0.008170934,0.00002107381,0.00003779811,0.00001905906,0.01136417,0.001922575],"study_design_scores_gemma":[0.3992863,0.0006747048,0.5941631,0.0002473042,0.0002545517,0.000005265117,0.001629777,0.0001052349,0.0001245617,0.00002251702,0.003242869,0.0002438199],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823872,0.0001018746,0.00001693021,0.008264402,0.0003541893,0.004255499,0.00004467352,0.0001098511,0.004465315],"genre_scores_gemma":[0.9948275,0.0001807764,0.0003514788,0.0002273463,0.0009514319,0.0005369217,0.0001273005,0.00003628994,0.002760959],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08530919,"threshold_uncertainty_score":0.9999517,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03887473312597239,"score_gpt":0.28644908395491,"score_spread":0.2475743508289376,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}